Barclays lowered the firm’s price target on Elevance Health to $611 from $621 and keeps an Overweight rating on the shares following the Q2 report. While the company’s Medicaid comments were “incrementally negative,” Elevance was able to fully absorb medical loss ratio pressure in current guidance and maintains conservative MLR assumptions in guidance, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- ELV Earnings: Elevance Reports Better-than-Expected Q2 Results
- Options Volatility and Implied Earnings Moves Today, July 17, 2024
- Elevance Health sees FY24 adjusted EPS ‘at least’ $37.20 per share
- Elevance Health reports Q2 adjusted EPS $10.12, consensus $10.01
- Notable companies reporting before tomorrow’s open